Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 3 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Aromatase inhibitors not linked to elevated colorectal cancer risk

12 Jan 2018

Aromatase inhibitors (AIs) do not appear to carry any increase in the risk of developing colorectal cancer, a study reports.

Drawing data from the United Kingdom Clinical Practice Research Datalink, researchers examined breast cancer patients aged ≥55 years who received AIs (n=9,701; median follow-up, 2.4 years) or tamoxifen (n=8,893; median follow-up, 2.9 years) as first-line hormonal therapy.

The risk of incident colorectal cancer in relation to AI vs tamoxifen was estimated by cumulative duration of use and time since initiation using high-dimensional propensity score-adjusted Cox proportional hazards models. All exposures were lagged by 1 year for latency considerations.

Results revealed that the risk of incident colorectal cancer was similar between the AI and tamoxifen groups (incidence rate, 150 per 100,000 person-years in both groups; adjusted hazard ratio [HR], 0.90; 95 percent CI, 0.53–1.52). This was true across analyses stratified by cumulative duration of AI use (p=0.54 for heterogeneity) and time since initiation (p=0.66 for heterogeneity).

The present data show no evidence of an elevated risk of colorectal cancer with AIs when compared with tamoxifen, and this should provide reassurance regarding the safety of AIs to women with breast cancer, researchers said.

“While it is not possible to rule out an increased risk of colorectal cancer with tamoxifen, our findings should be interpreted from context of clinical equipoise as tamoxifen remains the clinically meaningful alternative in management of oestrogen-receptor positive breast cancer,” they explained.

Additional studies with longer follow-up are warranted to confirm the present data, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 3 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.